Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of STERIS plc (NYSE:STE – Get Rating) by 16.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,305 shares of the medical equipment provider's stock after acquiring an additional 1,023 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in STERIS were worth $1,506,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of STE. Tcwp LLC acquired a new stake in STERIS during the 1st quarter valued at approximately $25,000. 1832 Asset Management L.P. purchased a new position in shares of STERIS during the 1st quarter valued at approximately $25,000. Riverview Trust Co purchased a new position in shares of STERIS during the 1st quarter valued at approximately $29,000. J.W. Cole Advisors Inc. purchased a new position in shares of STERIS during the 1st quarter valued at approximately $37,000. Finally, Standard Family Office LLC purchased a new position in shares of STERIS during the 1st quarter valued at approximately $43,000. 92.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently weighed in on STE shares. KeyCorp cut their target price on shares of STERIS from $256.00 to $240.00 and set an "overweight" rating for the company in a report on Thursday, August 4th. Piper Sandler started coverage on shares of STERIS in a report on Thursday, July 14th. They set an "overweight" rating and a $240.00 target price for the company. JMP Securities cut their target price on shares of STERIS from $270.00 to $250.00 in a report on Thursday, August 4th. StockNews.com raised shares of STERIS from a "hold" rating to a "buy" rating in a report on Thursday, August 11th. Finally, TheStreet raised shares of STERIS from a "c+" rating to a "b" rating in a report on Tuesday, August 2nd. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $252.00.

STERIS Price Performance

STERIS Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 23rd. Stockholders of record on Wednesday, September 7th were issued a dividend of $0.47 per share. This is a positive change from STERIS's previous quarterly dividend of $0.43. The ex-dividend date was Tuesday, September 6th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.12%. STERIS's dividend payout ratio is presently 50.40%.

About STERIS

(Get Rating)

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Featured Articles

• Get a free copy of the StockNews.com research report on STERIS (STE)
• MarketBeat: Week in Review 9/19 – 9/23
• Why Does Tesla Stock Remain Resilient?
• 2 Semiconductor Stocks To Watch For Reversals
• Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
• Is Costco's Post-Earnings Price Weakness A Good Time To Buy?

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE – Get Rating).

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.